Everstack Evidence

NMN in human trials

A few small trials, one showing a metabolic signal in a specific group; replication is limited.

Published 2026-10-15Sources checked 2026-10-152 sourcesEverstack research teamHow we work

Editorial section. Research summaries are not product claims and contain no product links or offers. A summary is never proof that any product works.

The question

What do controlled human studies of nicotinamide mononucleotide (NMN) show?

Study design

A 10-week randomized trial of 250 mg per day in 25 postmenopausal women with prediabetes and overweight or obesity, and a single-dose safety study in 10 healthy Japanese men. ^[1][2]

What they found

NMN increased muscle insulin sensitivity in the women's trial, with no change in body composition, blood pressure or plasma lipids. Single doses up to 500 mg were safe in the short safety study. ^[1][2]

Limitations

Tiny samples and short follow-up. Results in one group may not generalize. US regulatory status of NMN as a supplement has shifted, which is why we only consider it after counsel review.

What this does not mean

There is no human evidence that NMN extends lifespan.

Sources

1. Yoshino M et al. Science. 2021;372(6547):1224-1229. doi.org/10.1126/science.abe9985
2. Irie J et al. Endocr J. 2020;67(2):153-160. doi.org/10.1507/endocrj.EJ19-0313

Spot an error? Email hello@everstackhealth.com and we will correct it within 48 hours.